Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory ...
Vor Biopharma pivots to telitacicept for autoimmune diseases, backed by $491M cash to 2029. Click here to read an analysis of ...
DNA Damage Response (“DDR”) inhibitors, a category of drugs that work by blocking cancer cells' capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase (“PARP”) ...
Andrew Sales, Chief Product Officer and Chief Methodologist at Scaled Agile, is an experienced Lean, Agile, and DevOps leader ...
VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has declared a special cash dividend (the “Cash Dividend”) in connection with the previously ...
The Fosun subsidiary is paying the upfront fee, committing up to 1.12 billion yuan ($166 million) in milestones and agreeing ...
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...
Zacks Investment Research on MSN
NVO rallies 11% in a month: How should investors play the stock?
Novo Nordisk NVO shares have rallied 11.2% over a month as investors regained confidence in the company's obesity growth ...
VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has declared a special cash dividend (the "Cash ...
Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.
Amid an ongoing expansion of China’s volume-based procurement (VBP) scheme to lower drug costs, the Chinese government has ...
This pre-commercial biotech is worth more than some drugmakers that generate consistent sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results